Have a feature idea you'd love to see implemented?
Let us know!
MRUS Merus NV
Price (delayed)
$44.355
Market cap
$3.04B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.95
Enterprise value
$2.61B
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed
Highlights
MRUS's debt is down by 9% year-on-year
Merus's equity has soared by 79% YoY but it has decreased by 6% from the previous quarter
Merus's quick ratio has increased by 30% YoY but it has decreased by 19% QoQ
Merus's net income has decreased by 46% from the previous quarter and by 38% YoY
The EPS has contracted by 35% from the previous quarter and by 5% YoY
Key stats
What are the main financial stats of MRUS
Market
Valuations
Earnings
Shares outstanding
68.46M
Market cap
$3.04B
Enterprise value
$2.61B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.3
Price to sales (P/S)
84.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
72.77
Revenue
$35.93M
EBIT
-$251.64M
EBITDA
-$249.14M
Free cash flow
-$157.15M
Per share
Balance sheet
Liquidity
EPS
-$3.95
Free cash flow per share
-$2.3
Book value per share
$10.31
Revenue per share
$0.53
TBVPS
$12.35
Total assets
$844.68M
Total liabilities
$141.42M
Debt
$11.05M
Equity
$703.26M
Working capital
$586.2M
Debt to equity
0.02
Current ratio
8.32
Quick ratio
7.91
Net debt/EBITDA
1.69
Margins
Efficiency
Dividend
EBITDA margin
-693.4%
Gross margin
100%
Net margin
-680.6%
Operating margin
-642.8%
Return on assets
-36.4%
Return on equity
-45.4%
Return on invested capital
-103.2%
Return on capital employed
-32.9%
Return on sales
-700.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRUS stock price
How has the Merus stock price performed over time
Intraday
3.32%
1 week
-10.68%
1 month
-14.04%
1 year
87.47%
YTD
61.29%
QTD
-11.22%
Financial performance
How have Merus's revenue and profit performed over time
Revenue
$35.93M
Gross profit
$35.93M
Operating income
-$230.96M
Net income
-$244.56M
Gross margin
100%
Net margin
-680.6%
The operating margin has plunged by 80% YoY and by 15% from the previous quarter
MRUS's net margin has dropped by 76% year-on-year and by 43% since the previous quarter
Merus's net income has decreased by 46% from the previous quarter and by 38% YoY
MRUS's operating income is down by 42% YoY and by 17% QoQ
Growth
What is Merus's growth rate over time
Valuation
What is Merus stock price valuation
P/E
N/A
P/B
4.3
P/S
84.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
72.77
The EPS has contracted by 35% from the previous quarter and by 5% YoY
Merus's equity has soared by 79% YoY but it has decreased by 6% from the previous quarter
The P/B is 20% less than the last 4 quarters average of 5.4 but 8% more than the 5-year quarterly average of 4.0
The P/S is 174% higher than the 5-year quarterly average of 30.7 and 12% higher than the last 4 quarters average of 74.9
The revenue has declined by 21% year-on-year but it is up by 2.1% since the previous quarter
Efficiency
How efficient is Merus business performance
The ROS has plunged by 81% YoY and by 40% from the previous quarter
The ROE has grown by 28% YoY but it has contracted by 25% from the previous quarter
The ROA has declined by 27% since the previous quarter but it is up by 19% year-on-year
The ROIC has contracted by 21% from the previous quarter and by 8% YoY
Dividends
What is MRUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRUS.
Financial health
How did Merus financials performed over time
Merus's total assets has soared by 72% YoY but it has decreased by 5% from the previous quarter
The total liabilities has grown by 43% YoY but it has contracted by 2.8% from the previous quarter
MRUS's debt is 98% smaller than its equity
MRUS's debt to equity has surged by 100% since the previous quarter but it is down by 33% year-on-year
Merus's equity has soared by 79% YoY but it has decreased by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.